Liu Cuiping, Wang Lingshu, Merriam Jonah S, Shi Wei, Yang Eun Sung, Zhang Yi, Chen Man, Kong Wing-Pui, Cheng Cheng, Tsybovsky Yaroslav, Stephens Tyler, Verardi Raffaello, Leung Kwanyee, Stein Cody, Olia Adam S, Harris Darcy R, Choe Misook, Zhang Baoshan, Graham Barney S, Kwong Peter D, Koup Richard A, Pegu Amarendra, Mascola John R
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, 20892, USA.
Vaccine Research Center Electron Microscopy Unit, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
NPJ Vaccines. 2023 Aug 8;8(1):111. doi: 10.1038/s41541-023-00707-w.
While several COVID-19 vaccines have been in use, more effective and durable vaccines are needed to combat the ongoing COVID-19 pandemic. Here, we report highly immunogenic self-assembling SARS-CoV-2 spike-HBsAg nanoparticles displaying a six-proline-stabilized WA1 (wild type, WT) spike S6P on a HBsAg core. These S6P-HBsAgs bound diverse domain-specific SARS-CoV-2 monoclonal antibodies. In mice with and without a HBV pre-vaccination, DNA immunization with S6P-HBsAgs elicited significantly more potent and durable neutralizing antibody (nAb) responses against diverse SARS-CoV-2 strains than that of soluble S2P or S6P, or full-length S2P with its coding sequence matching mRNA-1273. The nAb responses elicited by S6P-HBsAgs persisted substantially longer than by soluble S2P or S6P and appeared to be enhanced by HBsAg pre-exposure. These data show that genetic delivery of SARS-CoV-2 S6P-HBsAg nanoparticles can elicit greater and more durable nAb responses than non-nanoparticle forms of stabilized spike. Our findings highlight the potential of S6P-HBsAgs as next generation genetic vaccine candidates against SARS-CoV-2.
虽然已有几种新冠病毒疫苗投入使用,但仍需要更有效、更持久的疫苗来对抗持续的新冠疫情。在此,我们报告了一种高度免疫原性的自组装严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白-乙肝表面抗原(HBsAg)纳米颗粒,其在HBsAg核心上展示了一种由六个脯氨酸稳定的WA1(野生型,WT)刺突S6P。这些S6P-HBsAg能结合多种结构域特异性的SARS-CoV-2单克隆抗体。在有或没有乙肝病毒预接种的小鼠中,用S6P-HBsAg进行DNA免疫引发的针对多种SARS-CoV-2毒株的中和抗体(nAb)反应比可溶性S2P或S6P,或编码序列与mRNA-1273匹配的全长S2P更有效、更持久。S6P-HBsAg引发的nAb反应持续时间比可溶性S2P或S6P长得多,并且似乎因预先接触HBsAg而增强。这些数据表明,SARS-CoV-2 S6P-HBsAg纳米颗粒的基因递送比稳定化刺突蛋白的非纳米颗粒形式能引发更强、更持久的nAb反应。我们的研究结果突出了S6P-HBsAg作为下一代抗SARS-CoV-2基因疫苗候选物的潜力。